本帖最后由 老马 于 2013-3-13 13:43 编辑
# P; w4 l# @- H* p$ n6 }
! V4 E2 z0 c* f( i. T健择（吉西他滨）+顺铂+阿瓦斯汀
) @% X. t1 I) ^" P* k+ _- T Gemzar +Cisplatin + Avastin) ?# f( p/ G; z: S$ X5 z0 `
http://annonc.oxfordjournals.org/content/21/9/1804.full
( Q" w5 l! `, {' O( GOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) : Y2 P: K) E: s( k: M2 V' ?4 \4 ^
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. . Z' U$ o" v$ C" T. y; x+ L% p# d: K+ G
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 K. L1 A* _, W3 s' Z0 w! b! k7 J
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 275)
+ Q0 T& Q$ N5 v/ l o3 i8 r6 Z( A
华为网盘附件：. I1 ~. p7 v1 t' L9 G! e$ Z
【华为网盘】ava.JPG* o V! Z& D3 \7 b1 j
|
显身卡
